• / Free eNewsletters & Magazine
  • / My Account
Home>Finance>Food>Food And Drug Administration

Food And Drug Administration

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. NovaBiotics Receives Orphan Drug Status from the US Food and Drug Administration (FDA ) for Lynovex® for the Treatment of Cystic Fibrosis

    NovaBiotics Receives Orphan Drug Status from the US Food and Drug Administration ( FDA ) for Lynovex® for the Treatment of Cystic Fibrosis

  2. Aduro BioTech Named One of Fierce 15 Leading Biotech Companies in 2014

    Aduro BioTech Named One of Fierce 15 Leading Biotech Companies in 2014

  3. Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer

    Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer

  4. Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma

    Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma

  5. Navidea Receives Orphan Drug Designation from FDA for Use of Lymphoseek® in Head and Neck Cancers

    Navidea Receives Orphan Drug Designation from FDA for Use of Lymphoseek® in Head and Neck Cancers

  6. VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity

    VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity

  7. Intuitive Surgical Robot Cleared by FDA for Base of Tongue Surgery

    Intuitive Surgical Robot Cleared by FDA for Base of Tongue Surgery

  8. Lilly's Type 2 Diabetes Drug Trulicity Gets FDA OK -- 2nd Update

    Lilly's Type 2 Diabetes Drug Trulicity Gets FDA OK -- 2nd Update

  9. Harvard Apparatus Regenerative Technology Obtains Orphan Drug Designation from U.S. Food and Drug Administration for HART-Trachea

    Harvard Apparatus Regenerative Technology Obtains Orphan Drug Designation from U.S. Food and Drug Administration for HART-Trachea

  10. NPS Pharma Stock Trading Halted Today; FDA Advisory Committee to Review Natpara® Biologics License Application

    NPS Pharma Stock Trading Halted Today; FDA Advisory Committee to Review Natpara® Biologics License Application

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.